The avian influenza virus H5N1 is shed in infected birds’ saliva, mucous, and feces. Still, other infected animals may shed bird flu viruses in respiratory secretions and other body fluids (e.g., cow milk). The virus can spread rapidly through poultry flocks and among wild birds. Thus, developing diagnostic tests to identify the virus at early stages before dissemination is crucial to contain a pandemic at early stages.
Detecting pathogens during a pandemic has mainly been based on PCR amplification. Although PCR is relatively fast, samples must undergo a lengthy extraction process, especially for environmental samples. Sequential sequencing also requires highly trained personnel, expensive equipment, and specialized facilities. Thus, the current project will develop a rapid test for the surveillance of H5N1 in human communities, point-of-care settings, animal farms, water supply, sediments of wetlands, farming- and human-derived sewages, animal processing plant sewage, and personnel working in animal husbandry.
The project will take place in BC. The project will develop engineered antibodies against the virus H5N1. These antibodies will be used to generate a rapid test. Samples from different environments, such as water supply, sediments of wetlands, farming- and human-derived sewages, animal processing plant sewage, etc., will be sampled, analyzed, and validated by the BCCDC using PCR techniques. The impact of the rapid test will be a fast delivery across the province for the early detection of the H5N1 virus to contain the dissemination and allow better management of the disease.
Since 2021, North America has experienced devastating outbreaks of Highly Pathogenic Avian Influenza virus (HPAIV) driven by HPAIV H5N1 clade 2.3.4.4b. Recently, it has spilled over into dairy cattle in the USA, raising concerns about its adaptation to mammals and potential human spread. Wild birds are the natural carriers of avian influenza viruses (AIV), but H5N1 can also infect wild mammals. Current HPAIV surveillance programs sample dead wildlife and use molecular methods that only detect active infection, underestimating the true number and distribution of infected animals. Serological tools measure antibodies from previous exposure and not active infection. However, current serology assays are not specific for HPAIV H5N1, can only be used in a limited number of species, and/or are too complex for large-scale implementation. To address this challenge, the BC based leadership team (Dr. Agatha Jassem at UBC/BC Centre for Disease Control and Dr. Chelsea Himsworth at BC Ministry of Agriculture) will design a new assay to detect antibodies specific for AIV. The test will detect multiple subtypes in one sample and can be used on different animal species with confirmatory testing done at the Canadian Food Inspection Agency (Dr. Yohannes Berhane) and cross-validation at Public Health Ontario (Drs. Maan Hasso and Vanessa Tran). This research will generate a standardized test crucial for nationwide comparative analyses. Its species independent nature allows for easy use in domestic animals and humans as needed, providing crucial insights into antibody reactivity, cross-reactivity, and infection reservoirs.
